#1 Clinical Trials Search in Europe

N-Hydroxy-3,4-Dimethoxy-N-Methyl-Benzamide

This article discusses clinical trials investigating the use of Custodiol-N, a solution containing N-Hydroxy-3,4-Dimethoxy-N-Methyl-Benzamide, for organ preservation in various types of transplantation. The trials aim to compare Custodiol-N with standard Custodiol solution in heart, liver, kidney, and pancreas transplants, focusing on safety, efficacy, and organ function outcomes in both pediatric and adult patients.

Table of Contents

What is Custodiol-N?

Custodiol-N is a new organ preservation solution being studied for use in organ transplantation. It is an improved version of an existing solution called Custodiol. Organ preservation solutions are special liquids used to protect and preserve organs after they are removed from a donor and before they are transplanted into a recipient.[1]

The active ingredients in Custodiol-N include amino acids like alanine, arginine, and histidine, as well as other substances like deferoxamine, sucrose, and various electrolytes. It also contains a unique compound called N-hydroxy-3,4-dimethoxy-N-methyl-benzamide (also known as LK-614).[1]

How Custodiol-N Works

Custodiol-N is designed to protect organs during the time between removal from the donor and transplantation into the recipient. This period is called cold ischemia time. The solution works in several ways:

  • It cools the organ to slow down its metabolism
  • It provides nutrients to support the organ’s cells
  • It helps prevent cell swelling and damage
  • It protects against harmful effects of oxygen deprivation

The goal is to keep the organ as healthy as possible until it can be transplanted and start functioning in the recipient’s body.[2]

Uses of Custodiol-N

Custodiol-N is being studied for use in preserving several types of organs for transplantation:

  • Hearts
  • Livers
  • Kidneys
  • Pancreas

It is used to flush the organ after removal from the donor and to store the organ during transport to the recipient.[3]

Ongoing Research

Several clinical trials are currently underway to evaluate the safety and effectiveness of Custodiol-N compared to the standard Custodiol solution:

  • A study in children undergoing heart transplantation[1]
  • A study in children having heart surgery for congenital heart defects[2]
  • A study in adults receiving kidney, liver, or pancreas transplants[3]
  • A study focused specifically on liver transplantation[4]

These studies are looking at various outcomes to determine if Custodiol-N provides any advantages over the current standard solution.

Potential Benefits

Researchers hope that Custodiol-N may offer several potential benefits compared to existing organ preservation solutions:

  • Better protection of the organ during cold storage
  • Improved organ function after transplantation
  • Reduced risk of complications like delayed graft function
  • Possibility of longer preservation times

However, these potential benefits still need to be proven through the ongoing clinical trials.[3][4]

Safety and Side Effects

A key focus of the current research is to assess the safety of Custodiol-N. Researchers are carefully monitoring for any adverse events or side effects in transplant recipients. So far, no major safety concerns have been reported, but the studies are still ongoing.[1][2]

It’s important to note that Custodiol-N is not a medication taken by patients directly. It is used only by medical professionals during the organ transplantation process.

Conclusion

Custodiol-N represents an exciting area of research in organ transplantation. If proven effective, it could potentially improve outcomes for transplant recipients. However, more research is needed before it can be widely adopted. Patients awaiting or considering organ transplantation should discuss the latest developments and options with their transplant team.

Study Type Organs Studied Patient Population Primary Endpoints Key Secondary Endpoints
Phase II, randomized, single-blind, multicenter Heart Children (birth to <18 years) Safety assessment (adverse events up to 3 months) Vital parameters, laboratory tests, hemodynamics, graft survival
Phase II, randomized, single-blind, multicenter Heart (congenital defects) Children (birth to <18 years) Safety and myocardial protection (CK-MB levels) Hemodynamics, echocardiography, cardiac injury markers
Phase III, randomized, single-blind, multicenter Kidney, Liver, Pancreas Adults (≥18 years) Graft function and injury after transplantation Organ-specific function markers, complications, survival rates
Phase III, randomized, single-blind, multicenter Liver Adults (≥18 years) Area under the curve of GPT (ALT) over 7 days Peak LDH, initial poor function, biliary complications

FAQ

  • What is Custodiol-N? Custodiol-N is an organ preservation solution containing N-Hydroxy-3,4-Dimethoxy-N-Methyl-Benzamide and other components. It is being studied as a potential improvement over the standard Custodiol solution for preserving organs during transplantation procedures.
  • What types of transplants are being studied with Custodiol-N? Custodiol-N is being studied in clinical trials for various types of organ transplants, including heart transplants in children, liver transplants, and combined kidney-pancreas transplants in adults.
  • How is Custodiol-N being compared to standard Custodiol? The clinical trials are comparing Custodiol-N to standard Custodiol in terms of safety, organ function, and preservation effectiveness. Researchers are measuring various outcomes such as adverse events, organ function markers, and patient survival rates.
  • What are the main objectives of these clinical trials? The main objectives of these trials include assessing the safety of Custodiol-N, evaluating its effectiveness in preserving organ function, and determining if it provides any advantages over standard Custodiol in terms of transplant outcomes and patient recovery.
  • Who can participate in these clinical trials? Participation criteria vary by study, but generally include patients undergoing specific types of organ transplants. Some trials focus on pediatric patients for heart transplants, while others include adult patients for liver, kidney, and pancreas transplants. Each trial has specific inclusion and exclusion criteria.

Ongoing Clinical Trials on N-Hydroxy-3,4-Dimethoxy-N-Methyl-Benzamide

  • Study comparing Custodiol-N and Custodiol organ preservation solutions for heart transplantation in children

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Organ Preservation in Kidney, Liver, and Pancreas Transplants Using Custodiol-N Solution Compared to a Drug Combination for Transplant Patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria

  • Study Comparing Custodiol-N and Custodiol for Heart Surgery in Children with Congenital Heart Defects

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Liver Transplantation: Comparing Custodiol-N Solution with a Drug Combination for Organ Preservation in Patients Undergoing Liver Transplant Surgery

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Custodiol-N: An organ preservation solution containing N-Hydroxy-3,4-Dimethoxy-N-Methyl-Benzamide and other components, being studied as a potential improvement over standard Custodiol for organ transplantation.
  • N-Hydroxy-3,4-Dimethoxy-N-Methyl-Benzamide: A key component in Custodiol-N solution, believed to have protective effects on organs during transplantation procedures.
  • Organ preservation: The process of maintaining the viability and function of organs outside the body during transplantation procedures.
  • Cardioplegia: A technique used to stop the heart temporarily during surgery, often using specialized solutions like Custodiol or Custodiol-N.
  • Delayed graft function: A complication in organ transplantation where the transplanted organ does not function immediately after surgery.
  • Extended criteria donors (ECD): Organ donors who may be older or have certain medical conditions, but whose organs are still considered suitable for transplantation.
  • Donation after circulatory death (DCD): A type of organ donation that occurs after the heart has stopped beating, as opposed to brain death donation.
  • Area under the curve (AUC): A statistical measure used to analyze the overall exposure to a drug or biomarker over time.
  • Alanine aminotransferase (ALT): An enzyme found primarily in the liver, used as a marker of liver health and function in transplantation studies.
  • Creatinine kinase (CK-MB): An enzyme found in heart muscle cells, used as a marker of heart damage or stress in transplantation studies.

References

  1. http://clinicaltrials.eu/trial/study-comparing-custodiol-n-and-custodiol-for-heart-transplantation-in-children/
  2. http://clinicaltrials.eu/trial/study-comparing-custodiol-n-and-custodiol-for-heart-surgery-in-children-with-congenital-heart-defects/
  3. http://clinicaltrials.eu/trial/study-on-organ-preservation-in-kidney-liver-and-pancreas-transplants-using-custodiol-n-solution-compared-to-a-drug-combination-for-transplant-patients/
  4. http://clinicaltrials.eu/trial/study-on-liver-transplantation-comparing-custodiol-n-solution-with-a-drug-combination-for-organ-preservation-in-patients-undergoing-liver-transplant-surgery/